NeuBase Therapeutics (STU:O7P) Change In Payables And Accrued Expense : €-2.70 Mil (TTM As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is NeuBase Therapeutics Change In Payables And Accrued Expense?

NeuBase Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2023 was €-0.46 Mil. It means NeuBase Therapeutics's Accounts Payable & Accrued Expense declined by €0.46 Mil from Jun. 2023 to Sep. 2023 .

NeuBase Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Sep. 2021 was €1.05 Mil. It means NeuBase Therapeutics's Accounts Payable & Accrued Expense increased by €1.05 Mil from Sep. 2020 to Sep. 2021 .

NeuBase Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for NeuBase Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics Change In Payables And Accrued Expense Chart

NeuBase Therapeutics Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

0.55

-2.65

1.22

0.02

1.05

NeuBase Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-0.01	-1.89	-0.14	-0.22	-0.46

NeuBase Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.70 Mil.

NeuBase Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuBase Therapeutics (STU:O7P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (STU:O7P) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

NBSE:USA O7P:Germany

Address

350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219

Website

https://www.neubasetherapeutics.com

NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.

NeuBase Therapeutics (STU:O7P) Headlines

No Headlines